Citations

Clear

148 citation(s) found for "Sherman, Mark".

An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals
Yabroff, K. Robin , Bradley, Cathy J. , Shih, Ya‐Chen Tina , Keating, Nancy L. , Gomez, Scarlett Lin , Banegas, Matthew P. , Sherman, Mark , Bradley, Cathy J , Ambs, Stefan , Hershman, Dawn L , Riaz, Nadeem , Yabroff, K Robin , Shih, Ya‐Chen Tina , Boehm, Amanda L. , Nogueira, Letícia , Sherman, Mark E. , Hershman, Dawn L. , Yu, James B. , Riaz, Nadeem , Stockler, Martin R. , Chen, Ronald C. , Franco, Eduardo L.

Mayo Clinic

JNCI Cancer Spectrum | October 9, 2023 | Volume: 7 | Issue: 5 | Pages: No page available

10.1093/jncics/pkad063 | PMID 37806772 Get It

An essential goal within reach: attaining diversity, equity, and inclusion for the Journal of the National Cancer Institute journals
Yabroff, K. Robin , Boehm, Amanda L. , Bradley, Cathy J. , Shih, Ya‐Chen Tina , Keating, Nancy L. , Gomez, Scarlett Lin , Banegas, Matthew P. , Hershman, Dawn L. , Sherman, Mark , Bradley, Cathy J , Ambs, Stefan , Hershman, Dawn L , Riaz, Nadeem , Yabroff, K Robin , Shih, Ya‐Chen Tina , Nogueira, Letícia , Sherman, Mark E. , Yu, James B. , Riaz, Nadeem , Stockler, Martin R. , Chen, Ronald C. , Franco, Eduardo L.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 9, 2023 | Volume: 115 | Issue: 10 | Pages: 1115-1120

10.1093/jnci/djad177 | PMID 37806780 Get It

Methylated DNA Markers for Sporadic Colorectal and Endometrial Cancer Are Strongly Associated with Lynch Syndrome Cancers
Bramblet, Rachel M. , Bakkum‐Gamez, Jamie N. , Foote, Patrick H. , Taylor, William R. , Berger, Calise K. , Gysbers, Brianna J. , Arndt, Jacquelyn , Chen, Longwen , Doering, Karen A. , Burger, Kelli N. , Samadder, N. Jewel , Slettedahl, Seth W , Foote, Patrick H , Taylor, William R , Berger, Calise K , Gysbers, Brianna J , Arndt, Jacquelyn , Chen, Longwen , Doering, Karen A , Burger, Kelli N , Mahoney, Douglas W , Sherman, Mark E , Kisiel, John B , Samadder, N Jewel , Slettedahl, Seth W. , Mahoney, Douglas W. , Sherman, Mark E. , Kisiel, John B.

Mayo Clinic

Cancer Prevention Research | September 20, 2023 | Volume: 16 | Issue: 11 | Pages: 611-620

10.1158/1940-6207.capr-23-0107 | PMID 37728516 Get It

Abstract Lynch syndrome (LS) markedly increases risks of colorectal and endometrial cancers. Early detection biomarkers for LS cancers could reduce the needs for invasive screening and surgical prophylaxis. To validate a panel of methylated DNA markers (MDM) previously identified in sporadic colorectal cancer and endometrial cancer for discrimination of these cancers in LS. In a case–control design, previously identified MDMs for the detection of colorectal cancer and endometrial cancer were assayed by qMSP on tissue-extracted DNA. Results were normalized to ACTB values within each sample. Least absolute shrinkage and selection operator models to classify colorectal cancer and endometrial cancer were trained on sporadic cases and controls and then applied to classify colorectal cancer and endometrial cancer, in those with LS, and cross-validated. We identified colorectal cancer cases (23 with LS, 48 sporadic), colorectal controls (32 LS, 48 sporadic), endometrial cancer cases (30 LS, 48 sporadic), and endometrial controls (29 LS, 37 sporadic). A 3-MDM panel (LASS4, LRRC4, and PPP2R5C) classified LS-CRC from LS controls with an AUC of 0.92 (0.84–0.99); results were similar for sporadic colorectal cancer. A 6-MDM panel (SFMBT2, MPZ, CYTH2, DIDO1, chr10.4479, and EMX2OS) discriminated LS-EC from LS controls with an AUC of 0.92 (0.83–1.0); the AUC for sporadic endometrial cancer versus sporadic controls was nominally higher, 0.99 (0.96–1.0). MDMs previously identified in sporadic endometrial cancer and colorectal cancer discriminate between endometrial cancer and benign endometrium and colorectal cancer and benign colorectum in LS. This supports the inclusion of patients with LS within future prospective clinical trials evaluating endometrial cancer and colorectal cancer MDMs and may provide a new avenue for cancer screening or surveillance in this high-risk population. Prevention Relevance: Lynch syndrome (LS) markedly increases risks of colorectal and endometrial cancers. Early detection biomarkers for LS cancers could reduce the needs for invasive screening and surgery. Methylated DNA markers previously identified in sporadic endometrial cancer and colorectal cancer discriminate between benign and cancer tissue in LS.
Abstract 3587: High resolution microCT to analyze the 3D morphology of microcalcifications in benign breast disease and breast cancer biopsy tissues
Schrup, Sarah E., Bel, Thomas de , Allers, Teresa, Seymour, Lisa R. , Schrup, Sarah E. , Hoskin, Tanya L. , Winham, Stacey J. , Radisky, Derek C. , Pacheco-Spann, Laura M. , Degnim, Amy C. , Sherman, Mark E.

Mayo Clinic

Cancer Research | June 9, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 3587-3587

10.1158/1538-7445.am2023-3587 Get It

Abstract Introduction: We used micro-computed tomography (microCT), a high-resolution imaging option, to detect and characterize microcalcifications (MCs) in three dimensions within pathology blocks of benign and malignant breast tissues. Methods: A set of 44 formalin-fixed, paraffin-embedded breast tissue blocks were assessed from n=22 women at two time points: benign breast biopsy and subsequent DCIS or DCIS with invasive disease breast cancer. Blocks were scanned using the Bruker Skyscan 1276 microCT at a resolution of 10 µm. SkyScan analysis CTAn software was utilized to prepare and analyze morphological parameters and multiple MCs contained within each block were averaged. Paired morphological parameters were compared between the benign and subsequent cancer samples within women using Wilcoxon signed-rank tests. Results: Median age of patients was 53 years (range 37-77 years) at initial benign biopsy and developed breast cancer at median of 5.6 years (range: 2.3-12.8 years) later. The initial benign biopsies were for proliferative disease without atypia in the majority (59%), while 23% had non-proliferative lesions and 18% atypical hyperplasia. The average structural model index was consistent with a near rod-like shape (median 2.99, range: 2.71-3.29). Paired comparisons between benign and cancer blocks showed that the average surface area of MCs was significantly higher in the cancer samples (p=0.0467), as was the average volume of MCs (p=0.0298) (Table 1). Conclusions: Preliminarily, we demonstrate that microCT of routinely prepared pathology blocks of breast tissues may be useful in characterizing the 3-D morphometry of MCs with suggestive differences in benign and cancer tissues. Given that MCs are a sentinel radiologic marker of DCIS but are common in benign breast disease, developing improved approaches for classifying MCs may have value in breast cancer screening and management. Table 1. Comparison of MC parameters in biopsy tissues (IQR = Interquartile Range). Benign sample from women who later developed breast cancer Breast cancer after prior benign sample Paired Differences (Cancer - Benign) Wilcoxon signed-rank p value (N=22) (N=22) (N=22) Number of Objects (Median (IQR)) 43.5 (14, 789) 69.5 (33, 289) -6 (-139, 67) 0.6830 Average Surface Area (mm2)(Median (IQR)) 0.0225 (0.0134, 0.0393) 0.0342 (0.0185, 0.0656) 0.0113 (-0.0027, 0.0322) 0.0467 Average Volume (mm3) (Median (IQR)) 0.0003 (0.0001, 0.0007) 0.0007 (0.0003, 0.0022) 0.0003 (0.000002, 0.0020) 0.0298 Average Surface Area/Volume (mm−1)(Median (IQR)) 214.92 (162.25, 328.39) 199.55 (151.89, 230.52) -20.85 (-86.05, 27.04) 0.1433 Average Structural Thickness (mm)(Median (IQR)) 0.0341(0.0196, 0.0446) 0.0395 (0.0336, 0.0505) 0.0074 (-0.0062, 0.0153) 0.1173 Average Structural Model Index (Median (IQR)) 2.9758 (2.8465, 3.1175) 3.0026 (2.9281, 3.0927) 0.0075 (-0.1073, 0.1381) 0.7656 Citation Format: Sarah E. Schrup, Thomas de Bel, Tanya Hoskin, Teresa Allers, Stacey Winham, Derek Radisky, Laura Pacheco-Spann, Lisa Seymour, Amy Degnim, Mark Sherman. High resolution microCT to analyze the 3D morphology of microcalcifications in benign breast disease and breast cancer biopsy tissues. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3587.
Abstract 5241: Association of polygenic risk scores with breast cancer risk among women with benign breast disease
Sherman, Mark E. , McCauley, Bryan M. , Gaudet, Mia M. , Pruthi, Sandhya , Aronson, Kristan J. , Guénel, Pascal , Chang‐Claude, Jenny , Yang, Xiaohong R. , Easton, Doug , Bolla, Manjeet K. , Vachon, Celine M. , Guénel, Pascal , Winham, Stacey J. , Vierkant, Robert A. , Scott, Christopher, Troester, Melissa A. , Radisky, Derek C. , Degnim, Amy C. , Murphy, Rachel A. , Truong, Thérèse , Becher, Heiko , García‐Closas, Montserrat , Chanock, Stephen Jacob , Ahearn, Thomas U. , Easton, Douglas F. , Vachon, Celine M.

Mayo Clinic

Cancer Research | June 9, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 5241-5241

10.1158/1538-7445.am2023-5241 Get It

Abstract Over one million biopsies are performed annually in the U.S. to evaluate suspicious breast lesions. Most biopsies lead to a diagnosis of benign breast disease (BBD) and these women have a 1.5- to fourfold increase in subsequent breast cancer (BC) risk compared with the general population. A polygenic risk score (PRS) including 313 common variants was developed to predict BC risk in the general population and has improved performance when added to existing BC prediction models. However, the value of PRS in risk prediction models among women with BBD has not been evaluated. To evaluate the role of the established PRS, BBD, and BC risk, we pooled data from 15,194 white women (6,706 BC cases and 8,488 controls) participating in five Breast Cancer Association Consortium case-control studies. BC risk associations were evaluated by self-reported BBD history and combinations of PRS expressed in tertiles using odds ratios (OR), considering the lowest category of PRS among women without BBD as the referent. Associations were also assessed in an independent case-cohort study (831 BC cases and 1,845 controls) using hazard ratios (HR). Among the case-control studies, the PRS was strongly associated with BC risk (OR=2.50 per standard deviation increase), and associations were similar in women with (OR=2.60) and without a history of BBD (OR=2.44, p-interaction=0.23). Women with BBD have a higher risk of BC than those without BBD within each level of PRS. Compared to women without BBD and in the lowest PRS category, those with BBD and PRS in the highest tertile had 5-fold increased odds of BC (OR = 5.38; 95% CI 4.73-6.13). Associations were similar in an independent case-cohort study. These findings indicate that BBD history and PRS are independent contributors to BC risk, and consideration of both simultaneously could improve breast cancer risk prediction. Future studies are needed to integrate PRS with other risk measures to refine absolute BC risk prediction among BBD patients. Associations of BC risk with combinations of PRS (tertiles) and history of BBD in five case-control studies and a case-cohort study from the Breast Cancer Association Consortium. Case-control studies Case-cohort study PRS score range History of BBD n BC cases n controls OR (95% CI)1 n BC cases n controls HR (95% CI)2 Tertile 1 (≤ -0.57) No 1009 2692 1.00 (Ref) 117 584 1.00 (Ref) Yes 508 902 1.54 (1.35-1.76) 69 163 2.05 (1.45-2.89) Tertile 2 (-0.58, -0.03) No 1469 2001 1.97 (1.78-2.17) 181 475 1.93 (1.48-2.51) Yes 760 798 2.65 (2.34-3.01) 108 170 2.99 (2.18-4.09) Tertile 3 (≥ -0.02) No 1910 1551 3.32 (3.01-3.67) 214 336 3.28 (2.52-4.26) Yes 1050 544 5.38 (4.73-6.13) 142 117 4.83 4.25-8.02) 1.Logistic regression analysis, adjusted for study site/genomic platform and age at enrollment. OR, odds ratio; CI, confidence interval.2.Cox proportional hazards regression analysis, accounting for the case-cohort study design and adjusted for age at enrollment. HR, hazard ratio; CI, confidence interval. Citation Format: Stacey J. Winham, Mark Sherman, Robert Vierkant, Bryan McCauley, Christopher Scott, Mia Gaudet, Melissa Troester, Sandhya Pruthi, Derek Radisky, Amy Degnim, Kristan Aronson, Rachel Murphy, Pascal Guenel, Therese Truong, Jenny Chang-Claude, Heiko Becher, Montserrat Garcia-Closas, Stephen Chanock, Thomas Ahearn, Xiaohong Yang, Doug Easton, Manjeet Bolla, Celine Vachon, Breast Cancer Association Consortium. Association of polygenic risk scores with breast cancer risk among women with benign breast disease. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5241.
Reproductive Events and Risk of Women's Cancers: From Parturition to Prevention
Sherman, Mark E. , Levi, Miriam , Teras, Lauren R. , Teras, Lauren R , Levi, Miriam E , Sherman, Mark E

Mayo Clinic

Cancer Prevention Research | June 1, 2023 | Volume: 16 | Issue: 6 | Pages: 309-312

10.1158/1940-6207.capr-23-0138 | PMID 37259802 Get It

Abstract Reproductive events beginning with pregnancy and ending with remodeling of the breast after cessation of breastfeeding alter breast structure and function and produce dramatic changes in systemic biology. In aggregate, these processes lower overall risk for breast, tubo-ovarian and endometrial cancers, albeit differentially by molecular subtypes of these tumors. Herein, we explore opportunities for research on protective mechanisms operative during this period of the life course, with the goal of encouraging studies to advance cancer prevention. See related article by Getz et al., p. 353
Endometrial safety of low-dose vaginal estrogens
Matharu, Harpreet, Stanczyk, Frank Z. , Mandelbaum, Rachel S. , Dancz, Christina Elizabeth , Sherman, Mark E.

Mayo Clinic

Menopause | April 6, 2023 | Volume: 30 | Issue: 6 | Pages: 650-658

10.1097/gme.0000000000002177 | PMID 37022294 Get It

Abstract It is estimated that up to 50% to 90% of postmenopausal women may experience genitourinary syndrome of menopause (GSM), which may have a detrimental impact on quality of life. One of the most effective modes of treatment of GSM is low-dose vaginal estrogens. Numerous studies have addressed the safety of these estrogens using endometrial biopsy and/or endometrial thickness on ultrasound. Based on these studies, the consensus is that low-dose vaginal estrogens do not substantially increase the risk of endometrial hyperplasia or cancer; however, the data are severely limited by short duration of follow-up. Although long-term trials are warranted, they are difficult to carry out, costly, and will not yield data for years. More immediate information regarding endometrial safety may be obtained from studies measuring endometrial tissue and serum concentrations of estradiol, estrone, and relevant equine estrogens after administration of different estrogen formulations and doses. This would allow us to understand better the metabolism of estrogens by the vagina and endometrium, and how much estrogen is reaching the endometrium. Here, we discuss metabolism, receptor binding, and signaling of estrogens in vaginal and endometrial tissue, and summarize the existing studies on the endometrial impact of low-dose vaginal estrogen treatment in postmenopausal women.
Abstract 4213: Comparison of benign breast disease subtypes and breast cancer risk among Hispanic and non-Hispanic white women in New Mexico
Lohani, Kush R. , Nibbe, Andrea M. , Seymour, Lisa R. , Vachon, Celine M. , Hill, Deirdre A. , Vierkant, Robert A. , Pacheco-Spann, Laura M. , Vachon, Celine M. , Sherman, Mark E. , Degnim, Amy C.

Mayo Clinic

Cancer Research | April 5, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 4213-4213

10.1158/1538-7445.am2023-4213 Get It

Abstract Introduction: Benign breast disease (BBD) is an important breast cancer (BC) risk factor, which may be classified as non-proliferative disease (NPD), proliferative disease without atypia (PDWA), or atypical hyperplasia (AH) for risk stratification. Data related to the frequency of specific types of BBD and their relationship to BC risk in the Hispanic American population are limited. To address this knowledge gap, we compared BBD and associated BC risk among Hispanic white (HW) and non-Hispanic white (NHW) in New Mexico (NM). Methodology: A retrospective IRB-approved study was performed of women 19 years or older residing in six counties in NM (Bernalillo, Sandoval, Sante Fe, Socorro, Torrance, Cibola/Valencia) between 1996 and mid-2007 to compare the frequency of BBD subtypes and BC risk among HW and NHW. We excluded women who had a history of BC prior to BBD diagnosis or who were diagnosed with BC within 6 months after BBD biopsy. Race and ethnicity were self-reported by women at the time of biopsy. BBD was categorized as NPD, PDWA, or AH based on medical records. Incident BC (in-situ or invasive) was ascertained via linkage to the NM Surveillance Epidemiology End Results (SEER) Registry and BC risk was assessed using standardized incidence ratios (SIRs), comparing the observed number of BC events to that expected based on the NM SEER six-county race- and ethnicity-specific incidence rates, accounting for age and calendar period. Results: Our analysis included 3,870 HW and 6,996 NHW women with BBD. The HW were younger (47.1 vs. 51 years) compared to NHW. HW women had slightly more NPD (69.4% vs. 66.6%) but less PDWA (26.2% vs. 29.4%) and similar frequency of AH (4.3% vs. 3.9%) as compared to NHW. Over a median post-BBD follow-up period of 13 years (range 6 months-17 years), 644 BCs were observed (4.81% in HW and 6.55% in NHW). The observed BC risk among women with BBD was higher than population-based expected rates (SIR 1.98, 95% CI 1.82-2.13, p<0.001) and showed expected increases in risk with increasing degrees of BBD abnormality: SIR=1.90 for NPD, 2.00 for PDWA, and 3.01 for AH. Comparing BC risk by ethnic subgroups, HW women had an overall risk of BC after BBD that was statistically indistinguishable from NHW women (SIR=2.17, 95% CI 1.86-2.48 in HW women, and SIR=1.91, 95% CI 1.73-2.08 in NHW women). Within the major subgroups of the BBD findings, there were no significant differences in risk of BC after BBD for HW versus NHW women. Conclusions: In this population-based study, benign breast disease subtypes and their associated breast cancer risk were similar among the Hispanic and non-Hispanic white women. Citation Format: Kush Raj Lohani, Andrea M. Nibbe, Robert A. Vierkant, Laura M. Pacheco-Spann, Lisa R. Seymour, Celine M. Vachon, Mark E. Sherman, Amy C. Degnim, Deirdre Hill. Comparison of benign breast disease subtypes and breast cancer risk among Hispanic and non-Hispanic white women in New Mexico. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4213.
Abstract 1000: Associations of parity and body mass index with NanoString digital spatial protein profiling in early onset breast cancer
Kachergus, Jennifer M., Shi, Ji , Wang, Chen , Thompson, E. Aubrey , Collins, Laura C. , Ruddy, Kathryn J. , Vierkant, Robert A. , Pacheco-Spann, Laura M. , Winham, Stacey J. , Snow, Craig , Couch, Fergus J. , Olson, Janet E. , Radisky, Derek C. , Degnim, Amy C. , Partridge, Ann H. , Sherman, Mark E.

Mayo Clinic

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 1000-1000

10.1158/1538-7445.am2023-1000 Get It

Abstract Purpose: Young women’s breast cancers (YBCs), defined herein as breast cancer (BC) diagnosed at age ≤ 40 years, are etiologically and biologically distinct from postmenopausal BCs, demonstrating a higher proportion of estrogen receptor (ER) negative subtypes and a worse prognosis. Studies have not assessed whether risk factors such as recent parity and body mass index (BMI) are linked to protein expression profiles in YBCs. Accordingly, we examined protein expression assessed with GeoMx® Digital Spatial Profiling (DSP) in 640 YBCs prepared as tissue microarrays (TMAs) in the Young Women’s BC Study (YWBCS). Methods: The YWBCS is a multi-institutional cohort of 1,297 women with incident BC diagnosed at age <40 years identified through medical record review, with risk factor data collected via questionnaires. TMAs including 1,505 cores of 640 YBCs that were collected prior to therapy and were suitable for molecular analysis were evaluated for 72 markers with NanoString GeoMx DSP. Associations of log-transformed biomarker expression with BMI and time from last live birth to BC diagnosis were carried out using linear mixed modeling approaches, accounting for multiple tumor tissue cores per individual. Results: Mean age at BC was 35.5 years (range 17-40). Tumor subtypes based on clinical immunostaining were the following: luminal B 46%; luminal A 36%; triple negative 12% and HER2+ 6%. Of 72 biomarkers tested, 53 (74%) were evaluable after QC and normalization. GeoMx ER and PR protein levels were higher in luminal A and luminal B YBCs than in HER2+ and TNBC (p=2x10-94 and 2x10-52, respectively), supporting the accuracy of the GeoMx assay. Compared to nulliparas or those with most recent birth > 3 years before BC, those who gave birth ≤ 3 years prior to BC had tumors with higher expression of PR (8x10-6) and ER (p=0.006), and lower expression of BCL-2 (p=0.006). In contrast, women with last birth ≥ 6 years prior to BC had higher expression of CD8 (p=0.006) and PD-1 (p=0.001) than nulliparas and those with more recent births. Compared to women with BMI between 18.5 and 29.9, those with higher or lower BMIs had higher expression of CD34 (p=0.0003), CD4 (p=0.0009) and CD14 (p=0.001). BCL-2 expression was higher among women with BMI < 18.5 compared to those with higher values (p=0.005). Women with BMI of 30+ had higher β2-microglobulin levels than those with lower BMIs (p=0.003). Inverse dose-response associations (with higher BMI related to lower levels) were observed for expression of ER (p=0.01), pan cytokeratin (p=0.004) and four proteins in the p13K/AKT signaling pathway (p ≤ 0.01 for each). Conclusions: Preliminarily, we identify differences in hormonal and immune markers in YBCs in relation to timing of births and BMI, suggesting that these factors may contribute to etiologic heterogeneity. Multivariate modeling is ongoing to incorporate molecular subtype and other risk factors. Citation Format: Robert A. Vierkant, Laura M. Pacheco-Spann, Stacey J. Winham, Jennifer M. Kachergus, Ji Shi, Craig Snow, Fergus J. Couch, Janet E. Olson, Chen Wang, Derek C. Radisky, Amy C. Degnim, E. Aubrey Thompson, Laura C. Collins, Kathryn J. Ruddy, Ann H. Partridge, Mark E. Sherman. Associations of parity and body mass index with NanoString digital spatial protein profiling in early onset breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1000.
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Köbel, Martin , Kang, Eunyoung , Weir, Ashley , Rambau, Peter , Nelson, Gregg , Meagher, Nicola S. , Riggan, Marjorie J. , Alsop, Jennifer , Anglesio, Michael S. , Beckmann, Matthias W. , Bisinotto, Christiani, Boisen, M.M. , Boros, Jessica , Brand, Alison H. , Carney, Michael E. , Coulson, Penny , Courtney‐Brooks, Madeleine , Cushing‐Haugen, Kara L. , Deen, Suha , El‐Bahrawy, Mona , Group, AOCS, Fischer, Anna , Gayther, Simon A. , Hartmann, Arndt, Hendley, Joy , Huang, Yajue, Jimenez‐Liñan, Mercedes , Jones, Michael E. , Kennedy, Catherine J. , Kluz, Tomasz , Koziak, Jennifer M. , Lesnock, Jaime, Lester, Jenny , Longacre, Teri A. , Lycke, Maria , Mateoiu, Constantina , McCauley, Bryan M. , McGuire, Valerie , Ney, Britta, Olawaiye, Alexander , Oršulić, Sandra , Osório, Ana , Paz‐Ares, Luis , Rothstein, Joseph H. , Ruebner, Matthias , Shah, Mitul , Sharma, Raghwa , Shvetsov, Yurii B. , Singh, Naveena , Talhouk, Aline , Whittemore, Alice S. , Widschwendter, Martin , Bowtell, David D.L. , Reis, Francisco José Cândido dos , Fasching, Peter A. , García, María J. , Goodman, Marc T. , Goode, Ellen L. , Huntsman, David G. , Kelemen, Linda E. , Kommoss, Stefan , Le, Nhu D. , Menon, Usha , Schildkraut, Joellen M. , Sieh, Weiva , Staebler, Annette , Ramus, Susan J. , Anglesio, Michael S , Erber, Ramona , Gilks, C. Blake , Shvetsov, Yurii B , Campbell, Ian G , Huntsman, David G , Ramus, Susan J , Köbel, Martin , Menon, Usha , Kennedy, Catherine J , Widschwendter, Martin , Jones, Michael E , Sieh, Weiva , Brand, Alison H , Bowtell, David D , Nelson, Gregg S , El-Bahrawy, Mona A , Kluz, Tomasz , Goodman, Marc T , Kang, Eun‐Young, Lee, Cheng‐Han , Ghatage, Prafull , Brooks‐Wilson, Angela , Cybulski, Cezary , Elishaev, Esther , Fereday, Sián , Group, AOCS, Barquín, Arántzazu , Gentry‐Maharaj, Aleksandra , Gronwald, Helena , Grube, Marcel , Harnett, Paul R. , Harris, Holly R. , Hartkopf, Andreas D , Hein, Alexander , Hernandez, Brenda Y. , Jakubowska, Anna , Lubiński, Jan , Cajal, Teresa Ramón y , Schoemaker, Minouk J. , Sherman, Mark E. , Steed, Helen , Storr, Sarah J. , Traficante, Nadia , Wang, Chen , Wilkens, Lynne R. , Winham, Stacey J. , Benı́tez, Javier , Berchuck, Andrew , Campbell, Ian , Cook, Linda S. , DeFazio, Anna , Doherty, Jennifer A. , Fortner, Renée T. , Gronwald, Jacek , Karlan, Beth Y. , Martin, Stewart G. , Modugno, Francesmary , Pharoah, Paul D.P. , Sundfeldt, Karin , Swerdlow, Anthony J. , Brenton, James D.

Mayo Clinic

The Journal of Pathology: Clinical Research | March 22, 2023 | Volume: 9 | Issue: 3 | Pages: 208-222

10.1002/cjp2.311 | PMID 36948887 Get It

AbstractOur objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high‐grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi‐institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36–3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11–2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.